West Pharmaceutical Services, Inc.
NYSE:WSTMedical - Instruments & Supplies
+$5.04 today
- Market cap
- $28.14B
- Beta
- 1.18
- P/E (TTM)
- 43.6
- EPS (TTM)
- $7.54
- Dividend yield
- 0.26%
Volume 0.59M
Average 0.85M
WST Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
West Pharmaceutical Services, Inc.NYSE: WST
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation grows, but more slowly than its trailing trend
Q2 FY2026 stock-based compensation of $10.9M rose 47.3% year over year, behind the +80.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 65.2% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.
Context
- Stock-based compensation amounted to 0.8% of revenue in FY2025, up 0.1 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +47.3% toward the trailing-twelve-month pace of +80.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 23.8M USD
- Year-over-year change
- +27.3%
- 4-year CAGR
- -10.7%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 23.8M | +27.3% |
| FY2024 | 2024-12-31 | 18.7M | -19.7% |
| FY2023 | 2023-12-31 | 23.3M | -1.7% |
| FY2022 | 2022-12-31 | 23.7M | -36.8% |
| FY2021 | 2021-12-31 | 37.5M | — |
Stock-Based Compensation vs competitors
How WST compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +80.1% is the highest of 4, against a peer median of -18.2%.
- Stock-based compensation amounts to 1.0% of revenue for WST, versus a peer median of 1.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $41.12M USD | -19.2% | +15.7% | 1.9% | |
| LTM Jun 2026 | $40.84M USD | -13.7% | — | 1.0% | |
| LTM Jun 2026 | $32.6M USD | +80.1% | +0.1% | 1.0% | |
| LTM Mar 2026 | $23.65M USD | -18.2% | -3.2% | 23.7% | |
| LTM Jun 2026 | €0 EUR | — | — | 0.0% | |
| Peer median (excluding WST) | — | -18.2% | +6.2% | 1.5% | |
Competitors are the stored peer set for WST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 661.8M | 585.9M | 593.4M | 492.7M | 493.7M |
| Depreciation & Amortization | 122.3M | 120.6M | 137.3M | 155.4M | 171.4M |
| Deferred Income Tax | (42.9M) | (30.8M) | 37.5M | 0 | (13.7M) |
| Stock-Based Compensation | 37.5M | 23.7M | 23.3M | 18.7M | 23.8M |
| Change in Working Capital | (193.8M) | (15M) | (20.4M) | 2.9M | 79.8M |
| Accounts Receivables | (123.5M) | (35.6M) | 4M | (58.8M) | 6.9M |
| Inventory | (86.5M) | (49.8M) | (13.5M) | 42M | (62.8M) |
| Accounts Payables | 16.8M | (2.8M) | 4.4M | 2.9M | 17.9M |
| Other Working Capital | (600K) | 73.2M | (15.3M) | 16.8M | 117.8M |
| Other Non-Cash Items | (900K) | 36.1M | 5.4M | (16.3M) | (200K) |
| Operating Cash Flow | 584M | 724M | 776.5M | 653.4M | 754.8M |
| Capital Expenditures | (253.4M) | (284.6M) | (362M) | (377M) | (285.9M) |
| Acquisitions (Net) | (2.2M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 2.5M | (3.6M) | (6.7M) | (1.7M) | 0 |
| Investing Cash Flow | (253.1M) | (288.2M) | (368.7M) | (378.7M) | (285.9M) |
| Debt Repayment | (2.2M) | (44.3M) | (2.3M) | (27.6M) | (1.1M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 18.2M |
| Common Stock Repurchased | (151.9M) | (222.2M) | (451.2M) | (566.6M) | (134M) |
| Dividends Paid | (51.1M) | (54.1M) | (57M) | (59.1M) | (61.2M) |
| Other Financing Activities | 37.1M | 27M | 50.9M | 30.7M | (7M) |
| Financing Cash Flow | (168.1M) | (293.6M) | (459.6M) | (622.6M) | (185.1M) |
| Effect of Forex Changes | (15.7M) | (10.5M) | 11.4M | (21.4M) | 22.9M |
| Net Change in Cash | 147.1M | 131.7M | (40.4M) | (369.3M) | 306.7M |
| Free Cash Flow | 330.6M | 439.4M | 414.5M | 276.4M | 468.9M |
West Pharmaceutical Services, Inc.
NYSE:WST
Intrinsic Alpha fair value
Locked
Current Price
$404.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.